Today we discuss how the election of Donald J. Trump to the white house as the 47th president of the United States impacts all the stuff we talk about on this podcast: Big Pharma, Weight Loss, GLP1 Medications, Regulations. We also talk about his team: Vivek Ramaswamy, Elon Musk, and others.

Let's really do a deep dive on the mechanisms of GLP1 that we haven't touched on previously. This is going to be a discussion for our long-time followers since we skip past a lot of introductory stuff.

Discussion about all the latest gossip on weight loss from around the country.

Discussing the FDAs recent reversal on compounding Terzepitide while they re-evaluate the shortage situation. This and more on today's episode.

You don't want to miss this episode! Today, we're looking into GLP1 pricing and how congress is putting BigPharma on the hotseat trying to understand why their drugs cost so much. All that and more on today's episode.

Today we discuss a major development: Novo Nordisk, the company behind WeGovy and Ozempic, is pushing the FDA to stop compounding pharmacies from manufacturing the compounded medications, citing the complexity of manufacture. Critics say it is just a ploy to secure profits.

Today we're going to do a deep dive into our sponsor and look at the services they offer and how they differ from other services in this space.

The discussion is about misdosing compounded medications and how this leads to adverse events. Ultimately, compliance is about being able to stay on a program for the long term benefits of weight loss, while managing the short term side effects. Not following protocol, or inexperienced providers, or errors in self medication can lead to challenges, even hospitalization in some cases (300+ reported cases). So, if you're going to use GLP1s do it safely, and with under the guidance of a professional. Do not go to medspas that promise low prices, only to supply you with badly dosed vials that are incorrectly administered.